Ernest Waaser

Chief Executive Officer

Ernest Waaser wurde im Juni 2011 zum Chief Executive Officer und Mitglied des Board of Directors  von Systagenix Wound Management ernannt. Bevor Ernest zu Systagenix  kam, hatte er die Position des President von Teleflex Medical inne, einem $1,5 Milliarden großen, global agierenden Hersteller von Einwegprodukten, u.a. mit bekannten Marken wie Arrow Vascular Access, Rusch Urologie und Anaesthesie sowie Hudson Beatmungsprodukte. Vor seiner Arbeit bei Teleflex war Ernest President und CEO von Hill-Rom, einem  globalen Hersteller von Krankenhausbetten und Spezialprodukten für Wund- und Beatmungstherapie. Vor seiner Zeit bei Hill-Rom verbrachte Ernest zehn Jahre im Geschäft mit medizinischen Bildgebungsverfahren einschließlich mehrerer Jahre als Chief Operating Officer von Sterling Diagnostic Imaging, einer erfolgreichen private equity-gestütztem Spin-off-Unternehmen des DuPonts Geschäfts.Ernest Waaser hat einen Hochschulabschluss in Kernenergietechnik an der Universität Mississippi State, sowie einen Master in Maschinenbau an der Universität South Carolina absolviert.

Joseph Woody

Non Executive Director

Joe Woody ist als Leiter des Bereiches “Vaskuläre Therapien” bei Covidien verantwortlich für das komplette Produktportfolio des Bereiches „Vascular“, welcher aus den drei Segmenten “Venöse Vaskuläre Therapien” (Dialyse-Katheter, Kompression, Therapien zur Vorsorge der chronischen venösen Insuffizienz sowie der tiefen venösen Insuffizienz und Produkte zur Intervention); “Periphere Vaskuläre Therapien” (periphere arterielle Stents, Ballone und Atherektomie); und “Neurovaskuläre Therapien” (embolische Coils zur Therapie von Gehirnaneurysma , Thrombektomie  und embolische Lösungen) besteht. Woody war maßgeblich an der Akquise von ev3 Inc., einem  450 mio $ Unternehmen aus dem Bereich endovaskuläre Therapien zur Behandlung der peripheren vaskulären sowie der neurovaskulären Krankheit, beteiligt. Woody trat im May 2009 bei Covidien ein, nachdem er verschiedene leitende Positionen bei Smith & Nephew, Inc, Alliance Imaging, Inc, EMC, Acuson und General Electric Medical Systems inne hatte. Er hat einen Bachelor-Abschluss der California State University, Fullerton.

Christopher M.Fashek

Non-Executive Director

Chris M. Fashek is the former Vice Chairman of KCI, a medical equipment manufacturer based in San Antonio, Texas. He has been a member of a number of philanthropic and industry boards holding the position of Chairman of the American Diabetic Association of South Texas and a board member of the YMCA of San Antonio.

Christian Ahrens

Non Executive Director

Christian Ahrens ist Managing Director bei One Equity Partners (OEP). Bevor er 2001 bei OEP anfing, arbeitete er für Goldman Sachs. Er bringt sich aktiv in der Investition der OEP´s Gesundheits und Reiseindustrie ein und unterstützt laufend das Gremium von Sytagenix, Arthrocare und Travel Leaders Group. Christian Ahrens erwarb seinen AB in moderner europäischer Geschichte an der Universität von Priceton.

Greg Belinfanti

Non Executive Director

Greg Belinfanti ist Managing Director bei One Equity Partners (OEP). Bevor er zu OEP ging, war er Vice President der Investment-Banking-Abteilung von Lehman Brothers mit dem Spezialgebiet globale Gesundheitsfürsorge. Greg Belinfanti ist außerdem Vorstandsmitglied bei Apollo Health Street und Prodigy Health Group. Er erwarb einen BA in Politikwissenschaften an der New York University, USA, und einen JD an der Harvard University, MA, USA.

Brad Coppens

Non Executive Director

Brad Coppens ist Managing Director bei OEP. Zuvor arbeitete er bis 2006 für JPMorgan Chase & Co. im Geschäftsbereich Investment Banking, Abteilung Fusionen und Übernahmen. Derzeit ist Greg Coppens Vorstandsmitglied bei Systagenix, Prodigy Health Group und X-Rite. Er erwarb seinen BBA in Buchhaltung und Finanzwesen an der Ross School of Business der University of Michigan, USA..

Gordie Nye

Non Executive Director

Gordie Nye ist derzeit Managing Director bei Group Outcome, LLC, sowie CEO bei Zeltiq Aesthetics. Zuvor war er CEO bei REVA Medical und President und CEO zweier früherer Geschäftsbereiche von Johnson & Johnson, „A“ Company Orthodontics und Critikon, nachdem diese bei einem Management Buyout übernommen worden waren. In diesem Zeitraum leitete er die umfassende Neugestaltung von Produktlinien, bevor diese an Sybron International (heute Teil von Danaher) und GE Medical Systems verkauft wurden. 2003 schloss Gordie Nye sich Prism VentureWorks als General Partner seines Life-Sciences-Investmentteams an, wo er sich auf Medizinprodukte spezialisierte. Während dieser Zeit war er Vorstandsmitglied mehrerer Portfolio-Unternehmen von Prism. Er war außerdem fast 15 Jahre lang im Bereich Konsumgüter und Freizeit in verschiedenen Marketing-, Verkaufs- und allgemeinen Managementpositionen bei Unternehmen wie Gillette, Olin Ski Company, Reebok und L.A. Gear tätig.
Gordie Nye hat einen MBA der Amos Tuck School of Business am Dartmouth College, NH, USA, inne, wo er auch sein Studium absolvierte.

Bob Stockman

Non Executive Director

Bob Stockman ist derzeit Vorstandsvorsitzender von REVA Medical, einem Medizintechnikunternehmen, das einen neuartigen, resorbierbaren, medikamentenfreisetzenden Stent entwickelt. Er ist außerdem President und Gründer von Group Outcome LLC, einer Investitionsbank mit Sitz in den USA, die ihr Kapital und das seiner Finanzpartner in Private-Equity- und Risikokapitalbeteiligungen bei Medizintechnikunternehmen investiert. Bob Stockman ist außerdem einer der Mitgründer und Startup-Geldgeber von CentriMed, das derzeit als Global HealthCare Exchange floriert, das weltweit größte elektronische Kommunkationsnetzwerk für das Gesundheitswesen. Bob Stockman und seine Partner waren Gründer und CEOs von mehr als 16 erfolgreichen Medizintechnikunternehmen. Bevor er Group Outcome LLC gründete, war er 18 Jahre lang für Johnston Associates und Narragansett Capital Corporation tätig, wo er sich auf Transaktionen im Gesundheitswesen konzentrierte. Bob Stockman war darüber hinaus Vorstandsmitglied bei einer Reihe von Gesundheitsunternehmen und -vereinigungen. Er erwarb einen MBA an der The Amos Tuck School des Dartmouth College, NH, USA, und einen BA am Harvard College, MA, USA.

Jack Wilkens

Non-Executive Director

Jack Wilkens is Chief Executive Officer of RevDia Corporation located in Miami. RevDia specializes in infectious disease point of care diagnostic testing and has recently launched a test for periodontal disease. Prior to RevDia Jack was Chief Operating Officer for Inverness Medical Innovations (now Alere – ALR-NYSE). IMI is the leading point of care rapid diagnostic company worldwide with sales over $1.9 billion and is the world's leading company in women's health diagnostics. Prior to the COO role, Mr. Wilkens was the Managing Director of Unipath, a wholly owned subsidiary of IMI, Inc. located in Bedford, England. During this period he was responsible for Women's Health diagnostics and led the launch of the IMI's digital pregnancy test the world's first consumer digital diagnostic test. He was Managing Director of IMI's and Johnson & Johnson's diabetes operations in Inverness, Scotland and responsible for IMI's European sales. The Scotland operation developed, manufactured and launched the world's leading blood glucose monitor. Jack was VP of Medical Imaging Systems with Sterling Diagnostics/AGFA responsible for X-ray systems and the launch of digital imaging platforms. He also worked for Polaroid Corporation for many years in digital medical imaging, manufacturing, product development and marketing. He was responsible for the design, building and operation of Polaroid's digital imaging facilities, the manufacturing of Polaroid’s instant negative film and was involved in the conception, development and marketing of many instant imaging business systems. Mr. Wilkens has a BS in Chemical Engineering from Michigan State University and an MBA from Western New England College.

Oern R. Stuge

Non-Executive Director

Oern R. Stuge is founder of ORSCO Life Sciences AG, through which he currently has several Executive & nonexecutive board directorships/advisory roles incl. Mediq NV, Nobel Biocare AG, Impulse Dynamics NV, Bonesupport AB, Quentiq AG, Aleva SA, HealthCap AB.
He joined the Board of Directors of Systagenix in October 2011.

Dr. Stuge has previously 12 years experience at Medtronic Inc. in different positions incl. Senior Vice President & President Cardiac Surgery, President EMEA, Latin America, Canada & India, member of the Executive Committee & Operating Committee.
Prior hitherto, 6 years experience at Abbott Laboratories, 7 years at a Norwegian start up incl. the position of CEO, and 6 years as a practicing physician.
He graduated as an MD from University of Oslo and received his MBA from IMD, Switzerland.

Rob Snyder

Certified Wound Specialist

Medical Director, Systagenix; Diplomat, American Board of Podiatric Surgery; Fellow, American College of Foot & Ankle Surgery; Certified Wound Specialist; Medical Director, Wound Healing Centre, University Hospital, Tamarac, Florida; Clinical Professor (Adjunct), Temple University College of Podiatric Medicine; Diplomat, American Academy of Wound Management; serves on the board of directors, President of the American Academy of Wound Management and President elect of the Association for the Advancement of Wound Care

Dr. Robert Snyder has been a podiatrist for 30 years; for the past 12 years, he has dedicated his practice to wound management and limb salvage. Dr. Snyder is a diplomat of the American Board of Podiatric Surgery and a Fellow of the American College of Foot and Ankle Surgeons. Additionally, he holds diplomat status in the American Academy of Wound Management, is a Certified Wound Specialist, and serves on the board of directors of that organization. He also serves on the board of directors of the Association for the Advancement of Wound Care.

He is currently completing a graduate degree in Wound Healing and Tissue Repair from Cardiff University, Wales College of Medicine, UK. Dr. Snyder has also been appointed Clinical Professor (Adjunct) at Temple University School of Podiatric Medicine.

Dr. Snyder serves as Medical Director of the Wound Care Center at University Hospital, Tamarac, Florida and was Medical Director of the Wound Healing Center at Northwest Medical Center, Margate, Florida. Dr. Snyder also serves as Medical Director of Systagenix Wound Management.

Dr. Snyder lectures extensively throughout the United States and abroad, and has published several book chapters and more than 75 articles in peer reviewed and trade journals. He serves on the editorial advisory boards of Ostomy Wound Management and Podiatry Management, and has recently been appointed as a reviewer for the New England Journal of Medicine. Dr. Snyder performs research concerning many innovative wound healing modalities and products. He was honored with the DuoDerm Research Scholarship in 1999 and studied at the Wound Healing Summer School at Oxford University, UK.

Dr. Snyder was recently designated a "Heavy Hitter in Medical Specialty Care" by the South Florida Business Journal. In October 2006, Podiatry Management acknowledged Dr. Snyder as one of "America's 175 Most Influential Podiatrists".

7301 N. University Drive, Suite 305
Tamarac, Florida 33321
(954) 721-4806 Tel
(954) 721-9841 Fax

David G. Armstrong

DPM,PhD

DPM, PhD: Professor of Surgery (with Tenure), University of Arizona; co-founded the Southern Arizona Limb Salvage Alliance; founder and co-chair of the International Diabetic Food Conference

Dr. Armstrong is Professor of Surgery (with Tenure) at The University of Arizona. Dr. Armstrong also holds a Masters of Science in Tissue Repair and Wound Healing from the University of Wales College of Medicine and a PhD from the University of Manchester College of Medicine, where he was appointed Visiting Professor of Medicine. He also co-founded the Southern Arizona Limb Salvage Alliance (SALSA).

Dr. Armstrong has produced more than 270 peer-reviewed research papers in more than two dozen scholarly medical journals as well as over two dozen book chapters and is co-Editor of the American Diabetes Association's (ADA) Clinical Care of the Diabetic Foot.

Dr. Armstrong was selected as one of the first six International Wound Care Ambassadors and is the recipient of numerous awards by national and international medical organizations including the inaugural Georgetown Distinguished Award for Diabetic Limb Salvage. In 2008, he was the 25th and youngest-ever member elected into the Podiatric Medicine Hall of Fame.

Dr. Armstrong is past Chair of Scientific Sessions for the ADA's Foot Care Council, and a past member of the National Board of Directors of the American Diabetes Association as well as a former commissioner with the Illinois State Diabetes Commission. He sits on the Infectious Disease Society of America's Diabetic Foot Infection Advisory Committee. Dr. Armstrong is the founder and co-chair of the International Diabetic Foot Conference (OF-Con), the largest annual international symposium on the diabetic foot in the world.

Matthias Augustin

Prof. Dr Med.

Professor for Health Economics & QoL Research Group, Department of Dermatology, University Clinics of Hamburg, Germany

Laura Bolton

PhD

PhD: Adjunct Associate Professor of the Department of Surgery, Bioengineering Section, New Jersey, USA; member of Editorial Boards of Wound Repair and Regeneration, Ostomy/Wound Management, Advances in Skin & Wound Care & WOUNDS publications; co-chairs the Association for the Advancement of Wound Care Guideline Department

Laura’s involvement in wound healing began in 1974 as a scientist for Johnson & Johnson conducting research on moist wound healing, growth factors, antimicrobials and electrical stimulation, with a dual role as biologist and educator starting in 1981 at the University of Medicine and Dentistry of New Jersey Department of Surgery, Bioengineering Section where she now serves as Adjunct Associate Professor of the Department of Surgery.

In 1987 Laura joined ConvaTec to lead the team that developed the DuoDERM CGF family of dressings using an evidence-based product development approach. In addition to evaluating new technologies and organizing wound care symposia on wound infection and cost effective wound care she has given more than 60 continuing education and Grand Rounds lectures at symposia, medical facilities and universities throughout North and South America, Asia, Europe and the Middle East and published more than 100 articles in peer-reviewed wound journals.

As a member of the Editorial Boards of Wound Repair and Regeneration, Ostomy/Wound Management Advances in Skin and Wound Care (Distinguished Reviewer Award, 2004) and WOUNDS (Guest Editor for the May 1994 and November 2007 issues addressing Outcomes in Wound Management and author of the bimonthly "Evidence Corner") Laura mentors current and future wound care clinicians and scientists.

In 2001, Laura was honored with the Sharon Baranoski Founder's Award at the 16th Annual Clinical Symposium for Advances in Skin Care and Wound Care for a career of mentoring and educating colleagues in wound care. The Journal of Wound Ostomy Continence Nurses, where Laura has contributed several "Evidence-based Report Cards", awarded her coauthors and herself the Nursing 2005 Manuscript Award for our 2004 article "Wound Healing Outcomes Using Standardized Care."

In January, 2006, Laura retired as ConvaTec's Global Director of Scientific Affairs.

Currently Laura co-chairs the Association for the Advancement of Wound Care Guideline Department and serves on the Guideline Steering Committee for the World Health Organization Global Initiative on Wound and Lymphoedema Management.

Laura is a member of the Boards of Directors for the Wound Healing Society and C3: Continuum of Care Coalition and is Chief Scientific Advisor for Derma Sciences. Her consulting company, BoltonSCI, LLC, exists to encourage evidence-based wound and ostomy care practices, product development and marketing.

Franck Duteille

Prof.

MD: Head of Department of Plastic Reconstructive and Esthetic Surgery, University Hospital, Nantes, France

Dieter Mayer

Prof.

MD: Vascular Surgeon, EBSQ-VASC, FMH; Senior Consultant of Vascular Surgery & Head of Wound Care, Zurich University Hospital, Switzerland

Dr. Zena Moore

PhD, MSc, FFNMRCSI, PG, Dip, RGN

PhD, MSc, FFNMRCSI, PG Dip, RGN: Lecturer in Wound Healing & Tissue Repair & Research Methodology, Faculty of Nursing & Midwifery, Royal College of Surgeons in Ireland; Current President of European Wound Management Association and chair of the education committee

Dr. Moore is a registered nurse, from Dublin, Ireland, and has just completed her PhD studies' exploring repositioning for the prevention of pressure ulcers; this 3 year research programme was funded by a Clinical Research Fellowship from the Health Research Board of Ireland. Before undertaking her PhD, Dr. Moore was a lecturer at the Faculty of Nursing and Midwifery, Royal College of Surgeons in Ireland, where she coordinated the Post Graduate Diploma/MSc in Wound Management & Tissue Viability programme. Previous to taking up the post as a lecturer, Dr. Moore worked in the area of wound management and tissue viability for 11 years.

Dr. Moore received a post graduate diploma, with distinction, in wound healing & tissue repair from the University Of Wales College Of Medicine in 1998 and an MSc in wound healing & tissue repair in 2001 from the same university. In 2002 she received a Fellowship of the Faculty of Nursing & Midwifery, RCS.

Dr. Moore is actively involved in research in wound management and has undertaken a number of systematic reviews with the Cochrane wounds group and the Cochrane renal group. Furthermore, Dr. Moore has published over 55 articles and book chapters and has researched in many aspects of wound management which have been presented at local, national and international meetings.

Dr. Moore is a member of the Health Service Executive of Ireland's National Wound Management Guideline Development group and was also a member of the 2009 European Pressure Ulcer Advisory Panel/National Pressure Ulcer Advisory Panel pressure ulcer prevention and management guideline development group.

Dr. Moore is president of the European Wound Management Association, where she also chairs the education committee.

Dr. Moore is a member of the World Health Organisation's Global Initiative in Wound and Lymphoedema Care and a member of EUCOMED advanced wound care sector.

Prof. Marco Romanelli

MD, PhD

MD, PhD: Consultant Dermatologist, Department of Dermatology, University of Pisa, Italy; Director Wound Healing Research Unit, University of Pisa; leads a research group actively involved in clinical, laboratory and educational activities

Dr. Marco Romanelli is a Board certified, Consultant Dermatologist at the Department of Dermatology, University of Pisa and received a PhD in Experimental Dermatology from the University of Naples. He is currently director of the Wound Healing Research Unit within the University of Pisa in Italy and leads a research group actively involved in clinical, laboratory and educational activities.

He is founding member and Past-President and board member of the European Pressure Ulcer Advisory Panel (EPUAP). He is currently Immediate Past President and Council member of the European Wound Management Association (EWMA), Executive Board member of the World Union Wound Healing Society (WUWHS). He is also Past President of the Italian Association for Cutaneous Ulcer (AIUC).

He has a special interest in wound assessment using physical measurements, inflammatory ulcers, biochemical markers in wound healing and has published widely in this field, in which he continues to undertake research.

Dr. Romanelli is on the editorial board of the journals WOUNDS, Wound Repair and Regeneration, The International Journal of Lower Extremity Wounds, Journal of Wound Care, International Wound Journal, Acta Vulnologica & Journal of Tissue Viability Nurses Society.

Dr. Thomas E. Serena

MD, FACS, FACHM, FAPWCA

MD, FACS, FACHM, FAPWCA: Founder & Medical Director of Pennsylvania North Centers for Advanced Wound Care, USA; founder of the NewBridge Medical Research Corporation and emeritus member of the Board of Director of the Wound Healing Society

He completed his residency in Surgery at The Milton S. Hershey Medical Center with fellowship training in Plastic and Reconstructive Surgery at Southern Illinois University. He is a professor at Gannon University in Erie Pennsylvania where he has established a state-of-the-art research program including development of a novel acute wound-healing model.

To date he has opened and operates fourteen wound care centers from New York City to Tulsa Oklahoma. Dr. Serena has been the lead or Principal investigator in over 50 clinical trials, including testing blood platelets, antimicrobial dressings, growth factors, topical and parenteral antibiotics and bi-Iayered cell therapy. As a result of the overwhelming demand for his services as a researcher, he founded the NewBridge Medical Research Corporation, a non-profit corporation (501(c) 3) dedicated to advancing the science of wound healing.

He is recognized internationally as an expert in the field of wound healing: He has nearly 100 published papers and has given more than 200 invited lectures throughout the world. He consults for numerous wound care industrial partners in the development of new products for the wound care space. He is an emeritus member of the Board of Directors of the Wound Healing Society and recently was an author on four of the national guidelines for the treatment of chronic wounds. More recently he was elected Vice President of the American College of Hyperbaric Medicine. He is also on the board of directors of the Association for the Advancement of Wound Care.

R. Gary Sibbald

BSc, MD FRCPC (Med, Derm), MACP, FAAD, MEd, FAPWCA

Dr. Sibbald is a dermatologist and internist with a special interest in wound care and education. He is a professor of public health sciences and medicine at the University of Toronto. As a wound care educator, clinician and clinical researcher he is an international wound care key opinion leader.

Dr. Sibbald is the co-founder (1999) and course director of the International Interprofessional Wound Care Course (IIWCC). He is the director of the Masters of Science in Community Health (Prevention and Wound Care) at the Della Lama School of Public Health at University of Toronto.

Dr. Sibbald is the president of the World Union of Wound Healing Societies 2008-12.
He is a co-editor and chapter author of the Chronic Wound Care textbook with the 5th edition due in 2010. He has over 200 publications.

Dot Weir

RN, CWON, CWS

RN, CWON, CWS: Director of Wound Care for Osceola Regional Medical Center, Florida, USA; held posts of Treasurer & President of Association for Advancement of Wound Care

Dot is a registered nurse, received her wound certifications from the Wound, Ostomy and Continence Nurses Certification Board, and the American Academy of Wound Management, and has been practicing wound care since 1980. She has worked in acute care, long term and home care, and for the past 8 years has practiced in outpatient care. She is currently the Director of Wound Care for Osceola Regional Medical Center in Kissimmee, Florida.

Dot was a founding member and has held the office of Treasurer and President of the Association for the Advancement of Wound Care (MWC), and is also a member of the Wound Healing Society (WHS), the Wound, Ostomy and Continence Nurses Society (WOCN) and the Florida Association of Enterostomal Therapists (FAET). She is the Co-Chair of the Symposium on Advanced Wound Care, is co-editor of the journal Today's Wound Clinic, is on the faculty of the Wound Certification Prep Course, and is a consultant and speaker for several manufacturers. She has authored and co-authored multiple book chapters and articles on various aspects of wound care.

Thomas Wild

MD

MD: Department of Surgery, University of Vienna, Austria; President Elect of Austrian Wound Association

Ernest Waaser

Chief Executive Officer

Ernest Waaser wurde im Juni 2011 zum Chief Executive Officer und Mitglied des Board of Directors  von Systagenix Wound Management ernannt. Bevor Ernest zu Systagenix  kam, hatte er die Position des President von Teleflex Medical inne, einem $1,5 Milliarden großen, global agierenden Hersteller von Einwegprodukten, u.a. mit bekannten Marken wie Arrow Vascular Access, Rusch Urologie und Anaesthesie sowie Hudson Beatmungsprodukte. Vor seiner Arbeit bei Teleflex war Ernest President und CEO von Hill-Rom, einem  globalen Hersteller von Krankenhausbetten und Spezialprodukten für Wund- und Beatmungstherapie. Vor seiner Zeit bei Hill-Rom verbrachte Ernest zehn Jahre im Geschäft mit medizinischen Bildgebungsverfahren einschließlich mehrerer Jahre als Chief Operating Officer von Sterling Diagnostic Imaging, einer erfolgreichen private equity-gestütztem Spin-off-Unternehmen des DuPonts Geschäfts.Ernest Waaser hat einen Hochschulabschluss in Kernenergietechnik an der Universität Mississippi State, sowie einen Master in Maschinenbau an der Universität South Carolina absolviert.

David Milner

Chief Financial & Operating Officer

Mr. Milner joined Systagenix in 2008. Mr. Milner’s career in Finance and Operations spans over 25 years. Prior to joining Systagenix, Mr. Milner held executive positions in several private equity-sponsored companies, including Critikon, “A” Company Orthodontics, Environmental Lighting Concepts, Voit Sports and BioSafety.  Mr. Milner has a B.S. in Accounting from Indiana University and is a Certified Public Accountant.

Paolo Di Vincenzo

Vice President Global Marketing

Prior to joining Systagenix Paolo Di Vincenzo was European Marketing Director for Becton Dickinson (BD) Diagnostics, world leader for the safe collection and transport of diagnostics specimens, as well as instruments and reagent systems to accurately detect a broad range of infectious diseases, healthcare-associated infections and cancers.  Prior to joining BD in 2008, Mr Di Vincenzo was Country Manager for Roche Diagnostics, Diabetes Care, Portugal and CRM Lead for Iberia and Latin America, following a number of domestic and international senior roles in Marketing, Business Development, and Finance between the UK, Switzerland, Germany, US, and Singapore between 2001 and 2008, which saw him successfully leading global re-branding and new product launches.

Mr Di Vincenzo is a graduate of University of Brighton, UK and Politecnico di Torino, Italy.

Helen Trevor

Vice President HR

Helen Trevor is the Vice President, Human Resources for Systagenix Wound Management. With over 20 years experience in Human Resources in a variety of positions including unionised manufacturing environments and global support services.  Helen joined Systagenix after working for CR Bard in the UK.  She has a degree in Biology and a Post Graduate Diploma in Personnel Management.

Bill Pigg

Vice President Product Development And Quality

Bill Pigg, Vice President of Product Development and Quality, has responsibility for Research and Development, Regulatory Affairs and Quality Assurance. A joint honours graduate in Materials Science and Economics with a PhD in Composite Materials, Bill also holds a post-graduate diploma in Medical Device Innovation Management from the Scandinavian International Management Institute (SIMI) in Copenhagen. Bill has some 20 years experience in medical device Research and Development with companies such as Smith and Nephew, Johnson and Johnson and Systagenix, working on such diverse areas such as Surgical Gown and Drape, Surgical Gloves, Fracture Fixation and, for the majority of his career, Wound Management. Bill has worked in a variety of business environments from Research Association and Corporate Research Centre to near to market development groups and holds several patents.

Jon Warrick

Vice President, International Markets

Jon Warrick trägt als Vice President die Verantwortung für den internationalen Vertrieb außerhalb der USA und West Europa. Bevor Jon Warrick im Februar 2010 diese Position übernahm, betreute er von 2008 an als Vice President das Globale Marketing.

In seiner nunmehr 15-jährigen Tätigkeit für Johnson & Johnson und Systagenix im Bereich Wundversorgung hatte er verschiedene Positionen in  Forschung & Entwicklung, New Business  Development und Marketing sowie im internationalen Vertrieb  in den USA, Frankreich und UK inne. Jon Warrick erwarb seinen Bachelor of Science (BSc) in Biomedizin an der Bradford University und einen MBA an der Leeds University.